HK1217094A1 - 降低左旋多巴血漿濃度的患者間可變性的方法 - Google Patents
降低左旋多巴血漿濃度的患者間可變性的方法Info
- Publication number
- HK1217094A1 HK1217094A1 HK16105147.3A HK16105147A HK1217094A1 HK 1217094 A1 HK1217094 A1 HK 1217094A1 HK 16105147 A HK16105147 A HK 16105147A HK 1217094 A1 HK1217094 A1 HK 1217094A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- plasma concentrations
- patient variability
- reducing inter
- levodopa plasma
- levodopa
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 230000036470 plasma concentration Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716753P | 2012-10-22 | 2012-10-22 | |
| PCT/US2013/065834 WO2014066206A1 (en) | 2012-10-22 | 2013-10-21 | Reducing inter-patient variability of levodopa plasma concentrations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1217094A1 true HK1217094A1 (zh) | 2016-12-23 |
Family
ID=50545140
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100408.8A HK1212257A1 (zh) | 2012-10-22 | 2016-01-14 | 降低左旋多巴血漿濃度的患者間可變性的方法 |
| HK16105147.3A HK1217094A1 (zh) | 2012-10-22 | 2016-05-05 | 降低左旋多巴血漿濃度的患者間可變性的方法 |
| HK18113477.5A HK1254400A1 (zh) | 2012-10-22 | 2018-10-22 | 降低左旋多巴血漿濃度的患者間可變性的方法相關申請 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100408.8A HK1212257A1 (zh) | 2012-10-22 | 2016-01-14 | 降低左旋多巴血漿濃度的患者間可變性的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18113477.5A HK1254400A1 (zh) | 2012-10-22 | 2018-10-22 | 降低左旋多巴血漿濃度的患者間可變性的方法相關申請 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9295661B2 (zh) |
| EP (1) | EP2908804A4 (zh) |
| JP (2) | JP2015534988A (zh) |
| KR (1) | KR102237007B1 (zh) |
| CN (2) | CN107982246A (zh) |
| AU (3) | AU2013334947B2 (zh) |
| BR (1) | BR112015009086A2 (zh) |
| CA (1) | CA2888979A1 (zh) |
| HK (3) | HK1212257A1 (zh) |
| MX (2) | MX2021004656A (zh) |
| NZ (2) | NZ747373A (zh) |
| RU (1) | RU2682681C2 (zh) |
| SG (1) | SG11201503128TA (zh) |
| WO (1) | WO2014066206A1 (zh) |
| ZA (1) | ZA201503631B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015010601B1 (pt) | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | Composição farmacêutica e uso da composição |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| DK2630954T3 (en) * | 2002-03-20 | 2017-01-23 | Civitas Therapeutics Inc | PULMONAL SUBMISSION OF LEVODOPA |
| US7160913B2 (en) | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
| WO2009085306A1 (en) * | 2007-12-28 | 2009-07-09 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
| TW201304822A (zh) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| JP2016500690A (ja) * | 2012-10-22 | 2016-01-14 | サイヴィタス セラピューティックス，インコーポレイテッド | パーキンソン病の迅速な軽減のためのレボドパ製剤 |
-
2013
- 2013-10-21 WO PCT/US2013/065834 patent/WO2014066206A1/en active Application Filing
- 2013-10-21 RU RU2015119376A patent/RU2682681C2/ru active
- 2013-10-21 AU AU2013334947A patent/AU2013334947B2/en active Active
- 2013-10-21 MX MX2021004656A patent/MX2021004656A/es unknown
- 2013-10-21 NZ NZ747373A patent/NZ747373A/en unknown
- 2013-10-21 BR BR112015009086A patent/BR112015009086A2/pt not_active Application Discontinuation
- 2013-10-21 EP EP13849720.1A patent/EP2908804A4/en active Pending
- 2013-10-21 MX MX2015005039A patent/MX2015005039A/es unknown
- 2013-10-21 JP JP2015538100A patent/JP2015534988A/ja active Pending
- 2013-10-21 CN CN201711421648.6A patent/CN107982246A/zh active Pending
- 2013-10-21 KR KR1020157013720A patent/KR102237007B1/ko active IP Right Grant
- 2013-10-21 SG SG11201503128TA patent/SG11201503128TA/en unknown
- 2013-10-21 CN CN201380067428.1A patent/CN105050581B/zh active Active
- 2013-10-21 CA CA2888979A patent/CA2888979A1/en active Pending
- 2013-10-21 NZ NZ708415A patent/NZ708415A/en unknown
-
2015
- 2015-04-21 US US14/691,788 patent/US9295661B2/en active Active
- 2015-05-22 ZA ZA2015/03631A patent/ZA201503631B/en unknown
-
2016
- 2016-01-14 HK HK16100408.8A patent/HK1212257A1/zh unknown
- 2016-05-05 HK HK16105147.3A patent/HK1217094A1/zh unknown
-
2018
- 2018-10-22 HK HK18113477.5A patent/HK1254400A1/zh unknown
- 2018-10-24 AU AU2018253542A patent/AU2018253542B2/en active Active
- 2018-12-13 JP JP2018233049A patent/JP2019038857A/ja active Pending
-
2020
- 2020-10-08 AU AU2020250280A patent/AU2020250280B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018253542A1 (en) | 2018-11-22 |
| AU2018253542B2 (en) | 2020-07-02 |
| AU2020250280B2 (en) | 2022-06-02 |
| CA2888979A1 (en) | 2014-05-01 |
| US9295661B2 (en) | 2016-03-29 |
| CN105050581B (zh) | 2018-01-19 |
| KR102237007B1 (ko) | 2021-04-06 |
| CN107982246A (zh) | 2018-05-04 |
| AU2020250280A1 (en) | 2020-11-05 |
| NZ708415A (en) | 2018-11-30 |
| HK1254400A1 (zh) | 2019-07-19 |
| AU2013334947B2 (en) | 2018-08-09 |
| JP2015534988A (ja) | 2015-12-07 |
| US20160015663A1 (en) | 2016-01-21 |
| NZ747373A (en) | 2020-02-28 |
| ZA201503631B (en) | 2017-11-29 |
| EP2908804A4 (en) | 2016-07-13 |
| RU2682681C2 (ru) | 2019-03-20 |
| KR20150101993A (ko) | 2015-09-04 |
| RU2015119376A (ru) | 2016-12-10 |
| BR112015009086A2 (pt) | 2017-07-04 |
| MX2015005039A (es) | 2015-12-01 |
| JP2019038857A (ja) | 2019-03-14 |
| SG11201503128TA (en) | 2015-05-28 |
| HK1212257A1 (zh) | 2016-06-10 |
| CN105050581A (zh) | 2015-11-11 |
| MX2021004656A (es) | 2022-08-22 |
| WO2014066206A1 (en) | 2014-05-01 |
| AU2013334947A1 (en) | 2015-06-11 |
| EP2908804A1 (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214259A1 (zh) | 衍生物 | |
| HK1209767A1 (zh) | 艾杜糖- -硫酸酯酶的純化 | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| HK1203949A1 (zh) | 抑制劑 | |
| HK1211024A1 (zh) | 的抑制劑 | |
| SG10201709310WA (en) | Plasma source | |
| EP2881113A4 (en) | NEW APPLICATION OF POGOSTONE | |
| EP2898106A4 (en) | PLASMA-INDUCED SMOKING | |
| EP2805247A4 (en) | USE-RELATED SYNCHRONIZATION OF APPLICATION COMMUNICATION FUNCTIONS | |
| PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 | |
| EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
| HK1254400A1 (zh) | 降低左旋多巴血漿濃度的患者間可變性的方法相關申請 | |
| GB201316178D0 (en) | Plasma source | |
| EP2879681A4 (en) | INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6 | |
| GB2506357B (en) | Machining of an article |